IP Library Granted Patent US 8,865,643
Granted Patent B2
US 8,865,643 · App. 13/020,607 · Granted Oct 21, 2014

Recombinant surfactant protein D compositions and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,865,643
App. No.
13/020,607
Granted
Oct 21, 2014
Kind
B2
Abstract

We describe an rspd(n/CRD) polypeptide, fragment, homologue, variant or derivative thereof for use in a method of treatment or prophylaxis of a disease. A method of treating an individual suffering from a disease or preventing the occurrence of a disease in an individual is also described, in which the method comprises administering to the individual a therapeutically or prophylactically effective amount of an rspd (n/CRD) polypeptide, fragment, homologue, variant or derivative thereof. Preferably, the rspd (n/CRD) polypeptide and nucleic acid comprise SEQ ID NO: 1 and SEQ ID NO: 2, respectively.

Claims (3)

1. A method for clearing necrotic and apoptotic cells, said method comprising administering a therapeutically effective amount of a recombinant Surfactant Protein D (n/Carbohydrate Recognition Domain) (rSPD(n/CRD) polypeptide to an individual suffering from a lung disease or lung condition, other than an allergic lung condition, in which there is a need for a reduction in necrotic and apoptotic cells in the lung, wherein the rSPD(n/CRD) polypeptide is set out in SEQ ID NO: 1.

2. The method of claim 1 wherein the patient suffers from neonatal chronic lung disease, neonatal respiratory distress syndrome, adult respiratory distress syndrome, chronic obstructive pulmonary disease (COPD), sarcoidosis, cystic fibrosis, pulmonary fibrosis, emphysema, bacterial infection of the lung, viral infection of the lung, interstitial inflammatory lung disease, chronic inflammatory lung disease or neonatal chronic inflammatory lung disease.

3. The method of claim 1 or 2 , wherein reduction of necrotic and apoptotic cells is determined by annexin V and propidium iodide staining.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2018
From: MEDICAL RESEARCH COUNCIL
To: UNITED KINGDOM RESEARCH AND INNOVATION
Reel/Frame 046469/0108 →